-
Nov 9, 2023 | 
mondaq.com | Clara Greaney |James Miles
The Centers for Medicare and Medicaid Services' (CMS) new
program Making Care Primary (MCP), is anticipated to
begin July 1, 2024.
In a previous blog post Foley breaks down major
highlights of the new model.
On September 5, 2023, applications opened. Eligible
providers have until November 30, 2023 to submit their applications
to CMS.
-
Nov 7, 2023 | 
jdsupra.com | Clara Greaney |James Miles
The Centers for Medicare and Medicaid Services’ (CMS) new program Making Care Primary (MCP), is anticipated to begin July 1, 2024. In a previous blog post Foley breaks down major highlights of the new model. On September 5, 2023, applications opened. Eligible providers have until November 30, 2023 to submit their applications to CMS.
-
Nov 6, 2023 | 
natlawreview.com | Clara Greaney
The Centers for Medicare and Medicaid Services’ (CMS) new program Making Care Primary (MCP), is anticipated to begin July 1, 2024. In a previous blog post Foley breaks down major highlights of the new model. On September 5, 2023, applications opened. Eligible providers have until November 30, 2023 to submit their applications to CMS.
-
Nov 6, 2023 | 
lexblog.com | Clara Greaney |James Miles
The Centers for Medicare and Medicaid Services’ (CMS) new program Making Care Primary (MCP), is anticipated to begin July 1, 2024. In a previous blog post Foley breaks down major highlights of the new model. On September 5, 2023, applications opened. Eligible providers have until November 30, 2023 to submit their applications to CMS.
-
Jul 18, 2023 | 
mondaq.com | Clara Greaney |Lauren Carboni |Monica R. Chmielewski |Kyle Faget
On June 26, 2023, the U.S. Food and Drug Administration (FDA)
issued its first draft guidance entitled Psychedelic Drugs:
Considerations for Clinical Investigations Guidance for
Industry (Guidance), which highlights considerations for
sponsors developing psychedelic drugs for treatment of medical
conditions (e.g., psychiatric disorders, substance use
disorders) and for clinical trials that will be conducted under an
investigational new drug application (IND) specifically.
-
Jul 17, 2023 | 
lexblog.com | Clara Greaney |Lauren Carboni |Monica R. Chmielewski |Kyle Faget
On June 26, 2023, the U.S. Food and Drug Administration (FDA) issued its first draft guidance entitled Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry (Guidance), which highlights considerations for sponsors developing psychedelic drugs for treatment of medical conditions (e.g., psychiatric disorders, substance use disorders) and for clinical trials that will be conducted under an investigational new drug application (IND) specifically.
-
Jul 17, 2023 | 
natlawreview.com | Clara Greaney
Clara Greaney is an associate for the Business Law Department at Foley & Lardner LLP. Clara is based in the Los Angeles office where she is a member of the Health Care Practice Group. In 2019 Clara was selected for the Mayo-Foley Health Law Fellowship, consisting of summer internships with the Mayo Clinic Legal Department in Rochester, Minnesota (2019) and Foley (2020).
-
Jun 6, 2023 | 
mondaq.com | Clara Greaney |Claire Marblestone |Kyle Faget
At the May 9-10, 2023, Joint Meeting of the Nonprescription
Drugs Advisory Committee and the Obstetrics, Reproductive and
Urologic Drugs Advisory Committee, U.S. Food and Drug
Administration (FDA) advisers voted that the agency should grant a
bid to support making the birth control pill, Opill, available for
over-the-counter (OTC) use.
Opill is manufactured by Perrigo Company and is currently only
offered as prescription only.
-
Jun 2, 2023 | 
jdsupra.com | Kyle Faget |Clara Greaney |Claire Marblestone
At the May 9-10, 2023, Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee, U.S. Food and Drug Administration (FDA) advisers voted that the agency should grant a bid to support making the birth control pill, Opill, available for over-the-counter (OTC) use. Opill is manufactured by Perrigo Company and is currently only offered as prescription only.
-
Jun 1, 2023 | 
lexblog.com | Claire Marblestone |Kyle Faget |Clara Greaney
At the May 9-10, 2023, Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee, U.S. Food and Drug Administration (FDA) advisers voted that the agency should grant a bid to support making the birth control pill, Opill, available for over-the-counter (OTC) use. Opill is manufactured by Perrigo Company and is currently only offered as prescription only.
